ClinicalTrials.gg
RecruitingNCT06780670PSMAcTIONUpdated Sep 22, 2026

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

A Phase 2/3 interventional study of Investigators choice of SoC and AAA817 in Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 93 sites in 13 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Planned enrollment
10th of 70
443 · median 72
Started
2025
with 10 others
Phase 2/3
2 of 82
1 open now
Primary completion
2028-06
later than 13 of 24 live
Registered
65th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is the 10th largest by planned enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 13 of the 24 other live ones, and was the 65th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.

Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Read the detailed description

Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • post [177Lu]Lu-PSMA targeted therapy
  • PSMA-positive
  • mCRPC adults
  • Metastatic castration-resistant prostate cancer
  • AAA817
  • [225Ac]Ac-PSMA-617
  • PSMA-based targeted therapy
  • Standard of Care
  • SOC
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: ∙

  • adults ≥ 18 years of age.
  • performance status of 0 to 2.
  • histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
  • PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,
  • castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L).
  • Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.
  • ≥ 1 lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
  • as requested by the sponsor

Exclusion Criteria:

  • Any agents within 28 days prior to the day of randomization.
  • Any 225Ac-based investigational compound used prior to the day of randomization.
  • Participants with a history of who are neurologically unstable, symptomatic, or receiving for the purpose of maintaining neurologic integrity.
  • Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury)
  • Baseline xerostomia ≥ Grade 2 by v.5
  • History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system within the past 2 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed).

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
443 participants (estimated)

Study arms

  • Experimental
    Phase II: AAA817 Dose B

    AAA817 will be given for a number of cycles; a cycle = 8 weeks

    Drug: AAA817

  • Active comparator
    Phase III: Investigator's choice of SoC

    Participants will be given Standard of Care (SOC) treatment per Investigator's choice.

    Drug: Investigators choice of SoC

  • Experimental
    Phase II: AAA817 Dose A

    AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks

    Drug: AAA817

  • Experimental
    Phase III: Recommended Phase 3 Dose of AAA817

    Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks

    Drug: AAA817

Interventions

  • DrugInvestigators choice of SoC

    The control treatment in Phase III is investigator's choice of SoC

  • DrugAAA817

    The investigational treatment is AAA817

    Also known as: [225Ac]Ac-PSMA-617)

  • DrugAAA817

    The investigational treatment is AAA817

    Also known as: [225Ac]Ac-PSMA-617)

  • DrugAAA817

    Investigational treatment is the Dose B of AAA817

    Also known as: [225Ac]Ac-PSMA-617

06

What researchers measure

Primary outcomes

  1. Biochemical response rate (Phase II)

    Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement

    Time frame: from date of randomization up to approximately 24 months

  2. Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II

    Safety defined as the type, incidence and severity of AEs and SAEs, and deaths

    Time frame: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later

  3. Tolerability of the proposed dose of AAA817- Phase II

    Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure

    Time frame: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817

  4. Radiographic progression-free survival (rPFS)- Phase III

    Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

    Time frame: from date of randomization up to approximately 24 months

  5. Overall survival (OS)- Phase III

    Percentage of participants who are alive or who are lost to follow-up at the time of analysis

    Time frame: from date of randomization up to approximately 24 months

Secondary outcomes

  1. Radiographic progression-free survival (rPFS)- Phase II

    Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

    Time frame: from date of randomization up to approximately 24 months

  2. Progression free survival (PFS)- Phase II

    Percentage of Participants meeting Progression Free Survival

    Time frame: from date of randomization up to approximately 24 months

  3. Overall response rate (ORR)- Phase II

    Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR)

    Time frame: from date of randomization up to approximately 24 months

  4. Disease control rate (DCR)- Phase II

    Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD

    Time frame: from date of randomization up to approximately 24 months

  5. Overall survival (OS)- Phase II

    Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off

    Time frame: from date of randomization up to approximately 24 months

  6. Progression free survival (PFS) -Phase III

    Percentage of participants with PFS -defined as the time from date of randomization to first documented progression

    Time frame: from date of randomization up to approximately 24 months

  7. Overall response rate (ORR)- Phase III

    ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)

    Time frame: from date of randomization up to approximately 24 months

  8. Disease control rate (DCR) -Phase III

    DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD)

    Time frame: from date of randomization up to approximately 24 months

  9. Duration of response (DoR)- Phase III

    Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first.

    Time frame: from date of randomization up to approximately 24 months

  10. Time to first radiographic soft tissue progression (TTSTP)- Phase III

    Percentage of participants with confirmed first radiographic progression in soft tissue

    Time frame: from date of randomization up to approximately 24 months

  11. First symptomatic skeletal event (TTSSE)_Phase III

    Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first

    Time frame: from date of randomization up to approximately 24 months

  12. Prostate specific antigen (PSA) response -Phase III

    PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline

    Time frame: from date of randomization up to approximately 24 months

  13. Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III

    Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS)

    Time frame: from date of randomization up to approximately 24 months

  14. Time to worsening on the Worst Pain: Phase III

    Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference).

    Time frame: from date of randomization up to approximately 24 months

07

Study locations

93 of 93 sites recruiting
  • Honor Health Research Institute
    Scottsdale, Arizona 85258, United States
    Recruiting
  • VA Greater LA Healthcare System
    Los Angeles, California 90073, United States
    Recruiting
  • VA Palo Alto Health Care System
    Palo Alto, California 94304-1207, United States
    Recruiting
    • Pallavi Gautam · Contactpallavi.gautam@va.gov · 650-493-5000
    • Minal Vasanawala · Principal investigator
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
    Recruiting
  • Sansum Clinic
    Santa Barbara, California 93105, United States
    Recruiting
  • Saint Johns Cancer Institute
    Santa Monica, California 90404, United States
    Recruiting
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
    Recruiting
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
    Recruiting
  • Baptist Health South
    Miami, Florida 33173, United States
    Recruiting
  • AdventHealth
    Orlando, Florida 32804, United States
    Recruiting
  • University Cancer and Blood Center LLC
    Athens, Georgia 30607, United States
    Recruiting
    • Christen Nicole Cooper Pope · Contactnpope@universitycancer.com · +1 706 353 2990
    • Petros Nikolinakos · Principal investigator
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
  • University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • Indiana University
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Marie Burton · Contactmariburt@iu.edu
    • Nabil Adra · Principal investigator
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
    Recruiting
  • East Jefferson Hospital
    Metairie, Louisiana 70006, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • WA Uni School Of Med
    St Louis, Missouri 63110, United States
    Recruiting
    • Collin Welch · Contactc.welch@wustl.edu · 314-454-8293
    • Jeff Michalski · Principal investigator
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68154, United States
    Recruiting
  • New Jersey Urology LLC
    Voorhees Township, New Jersey 08043, United States
    Recruiting
  • Mount Sinai Hosp Med School
    New York, New York 10029, United States
    Recruiting
  • Associated Med Professionals of NY
    Syracuse, New York 13210, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
  • Central Ohio Urology Group
    Gahanna, Ohio 43230, United States
    Recruiting
  • Oregon Urology Institute
    Springfield, Oregon 97477, United States
    Recruiting
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Texas Oncology
    Dallas, Texas 75251, United States
    Recruiting
  • Urology San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Utah Intermountain Medical Center
    Murray, Utah 84107, United States
    Recruiting
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
  • Onco Hemato Asso of SW Virginia
    Roanoke, Virginia 24014, United States
    Recruiting
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109-1024, United States
    Recruiting
  • Medical College Of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Nadia Thomas · Contactnathomas@mcw.edu
    • Deepak Kilari · Principal investigator
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 01308-050, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 05652-000, Brazil
    Recruiting
  • Novartis Investigative Site
    Fuzhou, Fujian 350025, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
    Recruiting
  • Novartis Investigative Site
    Xian, Shanxi 710032, China
    Recruiting
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
    Recruiting
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100034, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100036, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, 510060, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200025, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200032, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300300, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300480, China
    Recruiting
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
    Recruiting
  • Novartis Investigative Site
    Beersheba, 8457108, Israel
    Recruiting
  • Novartis Investigative Site
    Haifa, 3109601, Israel
    Recruiting
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
    Recruiting
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
    Recruiting
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
    Recruiting
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Novartis Investigative Site
    Kashiwa, Chiba 2778577, Japan
    Recruiting
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
    Recruiting
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
    Recruiting
  • Novartis Investigative Site
    Yokohama, Kanagawa 2360004, Japan
    Recruiting
  • Novartis Investigative Site
    Chiba, 2608717, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8110213, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8120033, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
    Recruiting
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
    Recruiting
  • Novartis Investigative Site
    Ishikawa, 9208641, Japan
    Recruiting
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
    Recruiting
  • Novartis Investigative Site
    Putrajaya, Kuala Lumpur 62250, Malaysia
    Recruiting
  • Novartis Investigative Site
    Petaling Jaya, Selangor 46050, Malaysia
    Recruiting
  • Novartis Investigative Site
    Petaling Jaya, Selangor 46150, Malaysia
    Recruiting
  • Novartis Investigative Site
    Mexico City, Mexico City 14050, Mexico
    Recruiting
  • Novartis Investigative Site
    Huxquilucan, 52763, Mexico
    Recruiting
  • Novartis Investigative Site
    Singapore, 119228, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 168583, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 258499, Singapore
    Recruiting
  • Novartis Investigative Site
    Seoul, 03080, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 03722, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 05505, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 06591, South Korea
    Recruiting
  • Novartis Investigative Site
    Basel, 4031, Switzerland
    Recruiting
  • Novartis Investigative Site
    Bellinzona, 6500, Switzerland
    Recruiting
  • Novartis Investigative Site
    Bern, 3010, Switzerland
    Recruiting
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
    Recruiting
  • Novartis Investigative Site
    Taipei, 103616, Taiwan
    Recruiting
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
    Recruiting
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2028, 40 months after the start.

Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 17, 2025
StartActual
Feb 27, 2025
Primary completionEst.
Jun 27, 2028
CompletionEst.
Jul 19, 2033
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780670
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 27, 2025
Primary completion
Jun 27, 2028 (estimated)
Completion
Jul 19, 2033 (estimated)
Last update
Sep 22, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion